Literature DB >> 10329575

Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment.

H Plotnicky-Gilquin1, T Huss, J P Aubry, J F Haeuw, A Beck, J Y Bonnefoy, T N Nguyen, U F Power.   

Abstract

The relative immunopathogenic potential of a recombinant fusion protein incorporating residues 130-230 of respiratory syncytial virus (RSV-A) G protein (BBG2Na), formalin-inactivated RSV-A (FI-RSV), and phosphate-buffered saline (PBS) was investigated in mice after immunization and RSV challenge. FI-RSV priming resulted in massive infiltration of B cells and activated CD4(+) and CD8(+) T lymphocytes in mediastinal lymph nodes (MLN) and lungs, where eosinophilia and elevated IFN-gamma, IL-2, -4, -5, -10, and -13 mRNA transcripts were also detected. PBS-primed mice showed only elevated pulmonary IL-2 and IFN-gamma mRNAs, while an activated CD8(+) T cell peak was detected in MLN and lungs. Cell infiltration also occurred in MLN of BBG2Na-immunized mice. However, there was no evidence of T cell, B cell, or granulocyte infiltration or activation in lungs, while transient transcription of Th1-type cytokine genes was evident. The absence of pulmonary infiltration is unlikely due to insufficient viral antigen. Thus, this recombinant fusion RSV G fragment does not prime for adverse pulmonary immunopathologic responses. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10329575     DOI: 10.1006/viro.1999.9702

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

1.  Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.

Authors:  Lindsay Broadbent; Hong Guo Parke; Lyndsey J Ferguson; Andrena Millar; Michael D Shields; Laurent Detalle; Ultan F Power
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

2.  Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice.

Authors:  Fu-Shi Quan; Yonghwan Kim; Sujin Lee; Hong Yi; Sang-Moo Kang; Jadranka Bozja; Martin L Moore; Richard W Compans
Journal:  J Infect Dis       Date:  2011-10-01       Impact factor: 5.226

3.  Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice.

Authors:  U F Power; T Huss; V Michaud; H Plotnicky-Gilquin; J Y Bonnefoy; T N Nguyen
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Modulation of protective immunity, eosinophilia, and cytokine responses by selective mutagenesis of a recombinant G protein vaccine against respiratory syncytial virus.

Authors:  Yan Huang; Robert Anderson
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats.

Authors:  G A Prince; C Capiau; M Deschamps; L Fabry; N Garçon; D Gheysen; J P Prieels; G Thiry; O Van Opstal; D D Porter
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment.

Authors:  H Plotnicky-Gilquin; A Robert; L Chevalet; J F Haeuw; A Beck; J Y Bonnefoy; C Brandt; C A Siegrist; T N Nguyen; U F Power
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

7.  Nonglycosylated G-Protein Vaccine Protects against Homologous and Heterologous Respiratory Syncytial Virus (RSV) Challenge, while Glycosylated G Enhances RSV Lung Pathology and Cytokine Levels.

Authors:  Sandra Fuentes; Elizabeth M Coyle; Hana Golding; Surender Khurana
Journal:  J Virol       Date:  2015-05-27       Impact factor: 5.103

8.  Gamma interferon-dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragment.

Authors:  Helene Plotnicky-Gilquin; Dominique Cyblat-Chanal; Jean-Pierre Aubry; Thierry Champion; Alain Beck; Thien Nguyen; Jean-Yves Bonnefoy; Nathalie Corvaïa
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 9.  Structure and function of respiratory syncytial virus surface glycoproteins.

Authors:  Jason S McLellan; William C Ray; Mark E Peeples
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

10.  Current research on respiratory viral infections: Fifth International Symposium.

Authors:  Michael G Ison; Sebastian L Johnston; Peter Openshaw; Brian Murphy; Frederick Hayden
Journal:  Antiviral Res       Date:  2004-06       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.